Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study

Abstract Background Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin with comparable effectiveness but significantly lower cardiotoxicity than conventional anthracycline. This study aimed to evaluate the real-world effectiveness and safety of PLD versus epirubicin as n...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Jin Zhang, Hongchuan Jiang, Jian Zhang, Guoqiang Bao, Guoqiang Zhang, Haibo Wang, Xi Wang
Format:	Article
Language:	English
Published:	BMC 2021-12-01
Subjects:	Adjuvant chemotherapy Breast cancer Epirubicin Neoadjuvant chemotherapy Pegylated liposomal doxorubicin
Online Access:	https://doi.org/10.1186/s12885-021-09050-6